Premium
Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis
Author(s) -
Imamura Tomoyuki,
Ogata Masao,
Kohno Kazuhiro,
Tomo Tadashi,
Ohtsuka Eiichi,
Kikuchi Hiroshi,
Kadota Junichi
Publication year - 2006
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20544
Subject(s) - al amyloidosis , melphalan , medicine , amyloidosis , transplantation , multiple myeloma , fludarabine , autologous stem cell transplantation , nephrotic syndrome , stem cell , gastroenterology , immunology , chemotherapy , cyclophosphamide , immunoglobulin light chain , genetics , antibody , biology
No established treatments for systemic AL amyloidosis have been determined, and only four reports have described allogeneic stem cell transplantation for this disease. We report the case of a patient with orthostatic hypotension, diarrhea, nephrotic syndrome, and cardiac amyloidosis due to systemic AL amyloidosis. Reduced intensity allogeneic stem cell transplantation (RIST) was performed using a conditioning regimen comprising fludarabine 125 mg/m 2 and melphalan 90 mg/m 2 . Hematologically complete remission and symptomatic improvement were obtained without severe transplantation‐related complications. RIST may thus offer a useful treatment strategy for systemic AL amyloidosis complicated by cardiac amyloidosis. Am. J. Hematol. 81:281–283, 2006. © 2006 Wiley‐Liss, Inc.